About Pediapharm (CVE:PDP)
Pediapharm Inc. (Pediapharm) is a specialty pharmaceutical company. The Company distributes prescription medicines used to treat pathological conditions that mainly affect children from infancy to 18 years of age. The Company sells products and offers marketing services to the pharmaceutical industry, particularly related to pediatric care. It offers NYDA, a treatment indicated for eradication of head lice and its eggs. The products that the Company distributes originate from transactions whereby Pediapharm acquires intellectual property rights through a licensing agreement that enables Pediapharm to register the drug products with Health Canada in order to commercialize them. Pediapharm does not produce, manufacture or develop products, but rather licenses finished products and sells them. Pediapharm also commercializes non-prescription products (non-prescription drugs, medical devices, diagnostic products). The Company's subsidiary is Pediapharm Licensing Inc.
Industry, Sector and Symbol
Trailing P/E Ratio-5.8
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-26.38%
Return on Assets-11.84%
Pediapharm (CVE:PDP) Frequently Asked Questions
What is Pediapharm's stock symbol?
Pediapharm trades on the Canadian Venture Exchange (CVE) under the ticker symbol "PDP."
When will Pediapharm make its next earnings announcement?
Who are some of Pediapharm's key competitors?
Some companies that are related to Pediapharm include Aegerion Pharmaceuticals (AEGR), Amryt Pharma (AMYT), NovaBay Pharmaceuticals (NBY), Rexahn Pharmaceuticals (RNN), Abzena (ABZA), Scancell (SCLP), Ocera Therapeutics (OCRX), VolitionRX (VNRX), Electromed (ELMD), Biopharmx (BPMX), Scientific Digital Imaging (SDI), Futura Medical (FUM), Advanced Oncotherapy (AVO), ANGLE (AGL), Concordia International (CXR), Actinium Pharmaceuticals (ATNM), Can Fite Biopharma (CANF) and Surgical Innovations (SUN).
Who are Pediapharm's key executives?
Pediapharm's management team includes the folowing people:
- Pierre Lapalme, Chairman of the Board (Age 76)
- Sylvain Chretien, President, Chief Executive Officer, Director
- Roland Boivin, Chief Financial Officer
- Richard Labelle, Vice President - Sales and Marketing
- Benoit Hebert, Vice President - Business Development & Licensing
- Benoit Gravel, Director
Has Pediapharm been receiving favorable news coverage?
News articles about PDP stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pediapharm earned a coverage optimism score of 0.11 on Accern's scale. They also gave news headlines about the company an impact score of 46.34 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Pediapharm?
Shares of PDP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Pediapharm's stock price today?
One share of PDP stock can currently be purchased for approximately C$0.29.
How big of a company is Pediapharm?
Pediapharm has a market capitalization of C$28.85 million.
How can I contact Pediapharm?
Pediapharm's mailing address is 1 du Commerce Pl Suite 225, VERDUN, QC H3E 1A2, Canada. The company can be reached via phone at +1-514-7622626.
MarketBeat Community Rating for Pediapharm (PDP)MarketBeat's community ratings are surveys of what our community members think about Pediapharm and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Pediapharm (CVE:PDP) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Pediapharm (CVE:PDP) Earnings History and Estimates Chart
Pediapharm (CVE PDP) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|6/27/2018|| || || || || || || || |
|8/24/2017||Q1 2018||C($0.01)||C($0.01)||C$2.00 million||C$2.47 million||View||N/A|
|6/28/2017||Q4 2017||C($0.02)||C($0.02)||C$1.50 million||C$1.66 million||View||N/A|
|2/28/2017||Q3 2017||C($0.01)||C($0.01)||C$1.77 million||View||N/A|
|11/28/2016||Q2 2017||C($0.01)||C$1.88 million||View||N/A|
|8/18/2016||Q1 2017||C$0.02||C$0.89 million||View||N/A|
|6/27/2016||Q4 2016||C($0.02)||C$0.65 million||View||N/A|
|2/25/2016||Q3 2016||C($0.02)||C$1.02 million||View||N/A|
|11/30/2015||Q2 2016||C($0.01)||C$1.47 million||View||N/A|
|8/27/2015||Q1 2016||C($0.02)||C$0.61 million||View||N/A|
|7/20/2015||Q4 2015||C($0.03)||C$0.34 million||View||N/A|
|3/2/2015||Q3 2015||C($0.02)||C$0.92 million||View||N/A|
Pediapharm (CVE:PDP) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Pediapharm (CVE:PDP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Pediapharm (CVE PDP)
No insider trades for this company have been tracked by MarketBeat.com
Pediapharm (CVE PDP) News Headlines
Pediapharm (CVE:PDP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Pediapharm (CVE PDP) Stock Chart for Monday, March, 19, 2018